Chennai Journal

Migraine Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | AIMOVIG, Fremanezumab, LBR-101, Atogepant, Galcanezumab, Eptinezumab

 Breaking News
  • No posts were found

Migraine Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | AIMOVIG, Fremanezumab, LBR-101, Atogepant, Galcanezumab, Eptinezumab

May 15
08:07 2024
Migraine Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | AIMOVIG, Fremanezumab, LBR-101, Atogepant, Galcanezumab, Eptinezumab
Migraine Market
Migraine Companies are Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.

(Albany, USA) DelveInsight’s “Migraine Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast

 

Some of the key facts of the Migraine Market Report: 

  • The Migraine market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • All participants who had a headache within the previous 12 months prior to the survey between October 2019 and March 2020 were included in the BURDEN 2020 study, which was developed by the RKI and conducted by the market and social research institute USUMA GmbH. According to the survey, 40.4% of men and 57.5% of women reported having headaches in the previous 12 months. In both men and women, 6.0% and 1.2%, respectively, suffered from migraines
  • Migraine is the most prevalent neurological condition, according to German research community funding headache research in Essen 2021. Around 14% of German women and 8% of German men are affected. About 2% of people have a chronic form of the condition
  • Key Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
  • Key Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
  • The Migraine epidemiology based on gender analyzed that the prevalence of migraine in female is slightly higher than male
  • The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.
  • On April 2024, AbbVie announced results of a Randomized, Double-Blind, Parallel-Group, and Active Controlled Trial with Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE).
  • On April 2024, Pfizer announced results of a Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens.
  • On November 2023, AbbVie announced results of a Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, and Parallel-Group Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine

 

Migraine Overview

Migraine is a neurological disorder characterized by recurrent, debilitating headaches often accompanied by other symptoms such as nausea, vomiting, sensitivity to light, and sound. These headaches typically last from a few hours to several days and can significantly interfere with daily activities and quality of life. Migraines are believed to involve abnormal brain activity and changes in blood flow, although the exact cause is not fully understood. Certain factors such as genetics, hormonal fluctuations, environmental triggers, and underlying medical conditions may contribute to migraine development. There are several types of migraines, including with aura (preceded by sensory disturbances like flashes of light or tingling) and without aura. Migraine Diagnosis is based on a thorough medical history, symptom evaluation, and ruling out other possible causes of headaches. Treatment strategies for migraines include lifestyle modifications, such as identifying and avoiding triggers, as well as medications for acute relief and prevention. These may include pain relievers, triptans, anti-nausea drugs, preventive medications, and alternative therapies like acupuncture or biofeedback. A personalized approach to management, tailored to the individual’s specific symptoms and triggers, is often necessary for effective migraine control.

 

Get a Free sample for the Migraine Market Report – https://www.delveinsight.com/sample-request/migraine-market

 

Migraine Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Migraine Epidemiology Segmentation:

The Migraine market report proffers epidemiological analysis for the study period 2019–2034 in the 7MM segmented into:

  • Total Prevalence of Migraine
  • Prevalent Cases of Migraine by severity
  • Gender-specific Prevalence of Migraine
  • Diagnosed Cases of Episodic and Chronic Migraine

 

Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiology Forecast

 

Migraine Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Migraine Therapies and Key Companies

  • AIMOVIG: Amgen
  • Fremanezumab: Teva Pharmaceuticals
  • Galcanezumab: Eli Lilly and Company
  • propranolol LA: Anne Lindblad
  • Atogepant: Allergan
  • LBR-101: Teva Branded Pharmaceutical
  • Atogepant: AbbVie
  • Galcanezumab: Eli Lilly and Company
  • Marcaine: Tian Medical Inc.
  • Atogepant: Allergan
  • Galcanezumab: Eli Lilly and Company
  • Eptinezumab: H. Lundbeck A/S
  • TNX-1900: Tonix Pharmaceuticals, Inc.
  • IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.

 

Discover more about therapies set to grab major Migraine market share @ Migraine Treatment Market

 

Scope of the Migraine Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
  • Key Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
  • Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
  • Migraine Market Dynamics: Migraine market drivers and Migraine market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Migraine Unmet Needs, KOL’s views, Analyst’s views, Migraine Market Access and Reimbursement 

 

To know more about Migraine companies working in the treatment market, visit @ Migraine Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Migraine Market Report Introduction

2. Executive Summary for Migraine

3. SWOT analysis of Migraine

4. Migraine Patient Share (%) Overview at a Glance

5. Migraine Market Overview at a Glance

6. Migraine Disease Background and Overview

7. Migraine Epidemiology and Patient Population

8. Country-Specific Patient Population of Migraine 

9. Migraine Current Treatment and Medical Practices

10. Migraine Unmet Needs

11. Migraine Emerging Therapies

12. Migraine Market Outlook

13. Country-Wise Migraine Market Analysis (2019–2034)

14. Migraine Market Access and Reimbursement of Therapies

15. Migraine Market Drivers

16. Migraine Market Barriers

17.  Migraine Appendix

18. Migraine Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

·         On April 2024, AbbVie announced results of a Randomized, Double-Blind, Parallel-Group, and Active Controlled Trial with Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE).

·         On April 2024, Pfizer announced results of a Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens.

·         On November 2023, AbbVie announced results of a Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, and Parallel-Group Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage